Journal
CLINICS IN DERMATOLOGY
Volume 28, Issue 1, Pages 81-87Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.clindermatol.2009.03.002
Keywords
-
Categories
Funding
- Merke-Serono
- Wyeth
- Abbott
- Schering-Plough
- Janssen-Cilag
Ask authors/readers for more resources
During the last 30 years, the tremendous progress in our knowledge of the pathogenesis of psoriasis has led to the development of new agents, the so-called biologics, that have revolutionized the management of severe psoriasis. Dermatologists and patients see this emerging therapy as a new perspective in the state of the art in managing moderate to severe psoriasis. After a few years of use in daily practice, we may begin to analyze the power of the currently available biologic agents in the management of severe psoriasis from the perspective of facts. (C) 2010 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available